These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 17175310

  • 21. Experience with everolimus.
    Augustine JJ, Hricik DE.
    Transplant Proc; 2004 Mar; 36(2 Suppl):500S-503S. PubMed ID: 15041396
    [Abstract] [Full Text] [Related]

  • 22. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups.
    Transpl Int; 2007 Jan; 20(1):27-36. PubMed ID: 17181650
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
    Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L.
    Liver Transpl; 2006 Nov; 12(11):1640-8. PubMed ID: 16598777
    [Abstract] [Full Text] [Related]

  • 28. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
    Lehmkuhl H, Ross H, Eisen H, Valantine H.
    Transplant Proc; 2005 Dec; 37(10):4145-9. PubMed ID: 16387066
    [Abstract] [Full Text] [Related]

  • 29. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
    Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y.
    Transplantation; 2004 Jun 27; 77(12):1826-33. PubMed ID: 15223899
    [Abstract] [Full Text] [Related]

  • 30. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.
    Krämer BK, Neumayer HH, Stahl R, Pietrzyk M, Krüger B, Pfalzer B, Bourbigot B, Campbell S, Whelchel J, Eris J, Vitko S, Budde K, RADA2307 Study Group.
    Transplant Proc; 2005 Apr 27; 37(3):1601-4. PubMed ID: 15866684
    [Abstract] [Full Text] [Related]

  • 31. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
    Budde K, Neumayer HH, Lehne G, Winkler M, Hauser IA, Lison A, Fritsche L, Soulillou JP, Fauchald P, Dantal J, RADW 102 Renal Transplant Study Group.
    Nephrol Dial Transplant; 2004 Oct 27; 19(10):2606-14. PubMed ID: 15316094
    [Abstract] [Full Text] [Related]

  • 32. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 33. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H, Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 15; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [Abstract] [Full Text] [Related]

  • 34. Higher incidence of acute rejection in renal transplant recipients with low everolimus exposure.
    Romagnoli J, Citterio F, Favi E, Salerno MP, Tondolo V, Spagnoletti G, Renna R, Castagneto M.
    Transplant Proc; 2007 Apr 15; 39(6):1823-6. PubMed ID: 17692622
    [Abstract] [Full Text] [Related]

  • 35. Lower homocysteine levels in renal transplant recipients treated with everolimus: a possible link with a decreased cardiovascular risk?
    Farsetti S, Zanazzi M, Caroti L, Rosso G, Larti A, Marcucci R, Fedi S, Rogolino A, Cellai AP, Abbate R, Bertoni E, Salvadori M.
    Transplant Proc; 2010 May 15; 42(4):1381-2. PubMed ID: 20534308
    [Abstract] [Full Text] [Related]

  • 36. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
    Kovarik JM, Hartmann S, Bartlett M, Riviere GJ, Neddermann D, Wang Y, Port A, Schmouder RL.
    Biopharm Drug Dispos; 2007 Mar 15; 28(2):97-104. PubMed ID: 17230596
    [Abstract] [Full Text] [Related]

  • 37. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
    Hummel M.
    J Heart Lung Transplant; 2005 Apr 15; 24(4 Suppl):S196-200; discussion S210-1. PubMed ID: 15774322
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M, Crespo M, Millán O, Serón D, Torregrosa V, Jiménez O, Moreso F, Martorell J, Grinyo JM, Oppenheimer F.
    Transplant Proc; 2007 Sep 15; 39(7):2160-2. PubMed ID: 17889124
    [Abstract] [Full Text] [Related]

  • 39. FTY720 immunomodulation: optimism for improved transplant regimens.
    Ferguson R.
    Transplant Proc; 2004 Mar 15; 36(2 Suppl):549S-553S. PubMed ID: 15041404
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
    Ettenger R, Schmouder R, Kovarik JM, Bastien MC, Hoyer PF.
    Pediatr Transplant; 2011 Jun 15; 15(4):406-13. PubMed ID: 21585629
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.